J Clin Oncol 2009 Oct 1
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Related Questions
New answer by Medical Oncologist at Mayo Clinic (March 1, 2018)
Possibly...there seems to be an association between the intensity of uptake and response to somatostatin analogs (SSAs) in patients with G2/G3 NETs. Almost all express somatos...
New answer by Medical Oncologist at Mayo Clinic (May 16, 2021)
As far as I am concerned, the drugs are equally effective, assuming the drugs get delivered correctly. The advantages of lanreotide are, as others have mentioned, a more relia...